Department of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Department of Pediatrics, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Drug Dev Res. 2019 Mar;80(2):253-261. doi: 10.1002/ddr.21487. Epub 2018 Nov 25.
Asthma is termed as the induction of chronic inflammation in the airway lumen of lungs due to accumulation of inflammatory cells which affects normal breathing process. Prolonged accumulation of inflammatory cells leads to oxidative stress and suppression of antioxidant activities. Therefore, in our present investigation, a potential phenolic compound, Syringic acid was tested for the suppression of inflammatory markers toward an antiasthmatic activity in ovalbumin (OVA)-induced asthmatic mice model. As a result, the Syringic acid treatment was found to suppress the inflammatory cells; eosinophil, neutrophil, macrophage, lymphocyte, and other inflammatory markers including IL-4, IL-5, IL-13, and TNF-α in the BALF of OVA-induced asthmatic mice. Similarly, IgE levels were significantly reduced in the blood serum of Syringic acid treated mice groups. In this context, the IFN-γ levels were found enhanced in the BALF of Syringic acid treated asthmatic mice groups, expressing an anti-inflammatory response. Enzymatic and nonenzymatic antioxidants such as SOD, CAT, and GSH levels were found high in the Syringic acid treatment than the asthmatic control group, which depicts the antioxidant response of Syringic acid on asthmatic groups. Intriguingly, the ROS, NO , NO , and MDA levels were inhibited in the BALF of Syringic acid treated mice groups. The airway hyper-reactivity (AHR) was comparatively normal in the Syringic acid treatment as it was severe in the case of asthmatic control group. Consequently, the effect of Syringic acid is prominent in the treatment of asthma by controlling the accumulation of inflammatory cells, other inflammatory markers along with enhancement of antioxidant markers, suppression of ROS and controlling airway hyperreactivity. Hence, Syringic acid may be recommended for clinical trials in the treatment of asthma.
哮喘是由于肺部气道腔中炎症细胞的积累而导致的慢性炎症，这会影响正常的呼吸过程。炎症细胞的长期积累会导致氧化应激和抗氧化活性的抑制。因此，在我们目前的研究中，一种潜在的酚类化合物——丁香酸被测试用于抑制炎症标志物，以发挥其在卵清蛋白（OVA）诱导的哮喘小鼠模型中的抗哮喘活性。结果表明，丁香酸处理能够抑制炎症细胞；嗜酸性粒细胞、中性粒细胞、巨噬细胞、淋巴细胞和其他炎症标志物，包括在 OVA 诱导的哮喘小鼠的 BALF 中的 IL-4、IL-5、IL-13 和 TNF-α。同样，血清中 IgE 水平在接受丁香酸治疗的小鼠组中显著降低。在这种情况下，IFN-γ 水平在接受丁香酸治疗的哮喘小鼠组的 BALF 中升高，表达出抗炎反应。在接受丁香酸治疗的哮喘小鼠组的 BALF 中，酶和非酶抗氧化剂如 SOD、CAT 和 GSH 水平升高，这表明丁香酸对哮喘组具有抗氧化反应。有趣的是，在接受丁香酸治疗的小鼠组的 BALF 中，ROS、NO、NO 和 MDA 水平受到抑制。气道高反应性（AHR）在接受丁香酸治疗的小鼠中相对正常，而在哮喘对照组中则非常严重。因此，丁香酸通过控制炎症细胞的积累、其他炎症标志物以及增强抗氧化标志物、抑制 ROS 和控制气道高反应性来治疗哮喘的效果显著。因此，丁香酸可能被推荐用于临床试验，以治疗哮喘。
